Edoceo Devices is an emerging med-tech & biotech American company with exclusive and ground-breaking technology that could help in the fight against future viral and bacterial threats to our families, pets, livestock, and our normal way of life.
With your help, our priority is finalizing the development of these technologies to produce two proprietary point-of-need detection biosensors - with the goal of providing essential, rapid, early warning to the presence of pathogens:
Edoceo B-Detect and V-Detect have
the potential to change the world of rapid, portable, affordable, and accurate
testing for pathogens including virulent bacteria and the presence of a range
of viruses such as influenza, Zika, dengue, HIV/AIDS, hepatitis C and other viruses
impacting humans, dogs, cats and livestock.
These innovative detection
platforms are being developed for the aquaculture, veterinary, health care,
food processing and home monitoring markets, amongst others – Edoceo detection
devices are based on the work led by our Chief Science Officer, the multi-award-Winning
Dr. Kenneth Reardon - and in collaboration with scientists at Colorado State
University for technology exclusively licensed to Edoceo after many years of
research.
AND HELP OUR FUTURE WITH EDOCEO DEVICES
Please read the Offering Circular before making an investment decision.
Offering Circular
Dr. Reardon first became aware of
the everyday problems that virulent bacteria can cause when an elderly relative
developed a urinary tract infection (UTI).
From being the happy independent individual,
the family knew and loved, they withdrew overnight and transformed into a
confused, unsteady and dependent person.
The time to collect a sample, send to the lab and receive results can take up to several days and unchecked, UTI’s can lead to kidney infection, which can lead to sepsis.[1]
The surprising thing is that this is only a tiny part of the problem.
According to the Centers for Disease Control and Prevention (CDC): Food
poisoning makes roughly 48 million Americans sick each year. Of those, 128,000
become sick enough to need hospitalization. And of those, 3,000 people die. [5]
In addition to the
medical misery and loss of life, food-borne pathogens take a toll on the
economy.
Experts expect superbugs to cost a cumulative $100 trillion of economic output by 2050[6]. According to The Harvard Business Review, foodborne illnesses cost America $55 billion a year in medical treatment, lost productivity, and lost wages, not to mention litigation expenses[7].
The latest CDC estimates are that more than 2.8 million people in the U.S. get sick each year from superbugs, and these infections are the primary cause of death for 35,000 of them[8]. This number doesn’t include those infected by MRSA, a dangerous and often deadly staph infection.
It’s clear that if we don’t find a way to detect life-threatening bacteria faster, and treat infections sooner, more people will get sick … more will die … and bacteria and superbugs will pose an increasingly significant risk to people, animals, and economies.
Prototype image
This
is where Edoceo needs your help. We are currently seeking funding to fast-track
the development and production of a ground-breaking testing platform called
B-Detect, which is designed to:
Watch this video to discover why Edoceo Devices is a great opportunity for investors as it pioneers point-of-need testing devices for the COVID-19 disease and eventually viruses causing diseases like HIV, dengue fever, influenza, Zika, and Hepatitis C, plus domestic animal viruses, 160 bacterial pathogens, and superbugs!
Please read the Offering Circular before making an investment decision.
Offering Circular
The market
potential for Edoceo Devices’ testing technology could be measured in the
billions of dollars.
While initially focusing on the shrimp market, the goal is
to develop B-Detect to be used by major sectors and industries that touch
millions of households in the U.S. alone. These include:
In addition to the medical misery
and loss of life, food-borne pathogens take a huge toll on the economy.
Experts expect superbugs to cost a cumulative
$100 trillion of economic output by 2050. [17]
According to The Harvard Business Review, foodborne illnesses cost America $55 billion a year in medical treatment, lost productivity, and lost wages, not to mention litigation expenses.[18]
The latest CDC estimates are that more than 2.8 million people in the U.S. get sick each year from superbugs, & these infections are the primary cause of death for 35,000 of them[19].
This number does not include those infected by MRSA, a dangerous and often deadly staph infection
It is clear that if we don’t find a way to detect life-threatening bacteria faster, and treat infections sooner, more people will get sick … more will die … and bacteria and superbugs will pose an increasingly significant risk to people, animals, and economies.
Edoceo’s B-Detect device could one day become a vital weapon in the war on superbugs and other bacterial pathogens because it could eventually allow users around the world to quickly, easily, and inexpensively:
If you take advantage of this
private investment opportunity today, this may help Edoceo to develop and bring
to market B-Detect, potentially saving many lives and reducing the physical,
emotional, and financial impact harmful bacteria have.
The motivated management team behind Edoceo Devices have been carefully chosen for their successful track records in transforming great opportunities into successes – please consider helping them, and potentially helping our future health, by investing in Edoceo Devices from only $580 today to help them on their mission, and to have the opportunity to be a part of a great potential solution.
Please read the Offering Circular before making an investment decision.
Offering Circular
Did You Know You Can Invest with Your IRA?
Our offering is approved by and available as a self-directed IRA investment with:
Click here to learn more about how you can invest in EDOCEO DEVICES using your IRA. Or feel free to reach out to us and we would be happy to discuss the process with you.
Please read the Offering Circular before making an investment decision.
Offering Circular
All of the above opinions are based on our objective analysis of the facts available to us at the time of writing; please read the Offering Circular before making an investment decision – or, for clarification, please contact us here
Please read the Offering Circular before making an investment decision.
Offering Circular
Privacy Policy & Legal Disclaimers
Legal Disclaimer
Quara Devices Inc. (dba Edoceo Devices) Campaign
IMPORTANT NOTICE AND DISCLAIMER: All investments are subject to risk, which must be considered on an individual basis before making any investment decision. This is a paid advertisement to bring market awareness to Quara Devices Inc. (dba Edoceo Devices), its products and services, and a related private equity investment opportunity under Regulation A+ of the JOBS Act. This advertisement is not, and should not be construed to be, an offer to sell or a solicitation of an offer to buy any security. Neither this advertisement or Edoceo purport to provide a complete analysis of any company or its financial position. This advertisement is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular investor. Any investment should be made only after consulting a professional investment advisor and only after reviewing the financial statements and other pertinent corporate information about the company. Further, readers are advised to read and carefully consider the Risk Factors identified and discussed in the advertised company’s SEC and/or other government filings. Investing in securities, particularly illiquid securities, is speculative and carries a high degree of risk. Past performance does not guarantee future results. This advertisement contains forward-looking statements, including statements regarding Edoceo’s expected continual growth. Quara Devices Inc. (dba Edoceo Devices) notes that statements contained herein that look forward in time, which include everything other than historical information, involve risks and uncertainties that may affect the company’s actual results of operations. Factors that could cause actual results to differ include the size and growth of the market for the company’s products and/or services, the company’s ability to fund its capital requirements in the near term and long term, pricing pressures, etc. All trademarks used in this advertisement are the property of their respective trademark holders and no endorsement by such owners of the contents of this advertisement is made or implied. Devices Inc. (dba Edoceo Devices) is not affiliated, connected, or associated with, and are not sponsored, approved, or originated by, the trademark holders unless otherwise stated. No claim is made to any rights in any third-party trademarks.
Offering Circular
AN OFFERING STATEMENT REGARDING THIS OFFERING HAS BEEN FILED WITH THE SEC. THE SEC HAS QUALIFIED THAT OFFERING STATEMENT, WHICH ONLY MEANS THAT THE COMPANY MAY MAKE SALES OF THE SECURITIES DESCRIBED BY THE OFFERING STATEMENT. IT DOES NOT MEAN THAT THE SEC HAS APPROVED, PASSED UPON THE MERITS OR PASSED UPON THE ACCURACY OR COMPLETENESS OF THE INFORMATION IN THE OFFERING STATEMENT. YOU MAY OBTAIN A COPY OF THE OFFERING CIRCULAR THAT IS PART OF THAT OFFERING STATEMENT FROM:
YOU SHOULD READ THE OFFERING CIRCULAR BEFORE MAKING ANY INVESTMENT HERE.
THE OFFERING MATERIALS MAY CONTAIN FORWARD-LOOKING STATEMENTS AND INFORMATION RELATING TO, AMONG OTHER THINGS, THE COMPANY, ITS BUSINESS PLAN AND STRATEGY, AND ITS INDUSTRY. THESE FORWARD-LOOKING STATEMENTS ARE BASED ON THE BELIEFS OF, ASSUMPTIONS MADE BY, AND INFORMATION CURRENTLY AVAILABLE TO THE COMPANY’S MANAGEMENT. WHEN USED IN THE OFFERING MATERIALS, THE WORDS “ESTIMATE,” “PROJECT,” “BELIEVE,” “ANTICIPATE,” “INTEND,” “EXPECT” AND SIMILAR EXPRESSIONS ARE INTENDED TO IDENTIFY FORWARD-LOOKING STATEMENTS, WHICH CONSTITUTE FORWARD LOOKING STATEMENTS. THESE STATEMENTS REFLECT MANAGEMENT’S CURRENT VIEWS WITH RESPECT TO FUTURE EVENTS AND ARE SUBJECT TO RISKS AND UNCERTAINTIES THAT COULD CAUSE THE COMPANY’S ACTUAL RESULTS TO DIFFER MATERIALLY FROM THOSE CONTAINED IN THE FORWARD-LOOKING STATEMENTS. INVESTORS ARE CAUTIONED NOT TO PLACE UNDUE RELIANCE ON THESE FORWARD-LOOKING STATEMENTS, WHICH SPEAK ONLY AS OF THE DATE ON WHICH THEY ARE MADE. THE COMPANY DOES NOT UNDERTAKE ANY OBLIGATION TO REVISE OR UPDATE THESE FORWARD-LOOKING STATEMENTS TO REFLECT EVENTS OR CIRCUMSTANCES AFTER SUCH DATE OR TO REFLECT THE OCCURRENCE OF UNANTICIPATED EVENTS.
[1]
https://www.webmd.com/women/uti-complications#2
[2]
https://finneganmedicalsupply.com/blogs/news/utis-in-elderly-patients-with-incontinence
[3] Flores-Mireles et al.,
2015
[4]
https://www.nia.nih.gov/health/bladder-health-older-adults
[5]
https://www.cdc.gov/foodborneburden/2011-foodborne-estimates.html
[6]
https://www.cnbc.com/2016/05/19/superbugs-could-cost-100-trillion--and-millions-of-lives--by-2050-report.html
[7]
https://hbr.org/2019/05/to-improve-food-inspections-change-the-way-theyre-scheduled
[8]
https://www.nrdc.org/experts/david-wallinga-md/cdc-deaths-drug-resistant-infections-rise
[9]
http://www.fao.org/fishery/countrysector/naso_usa/en
[10]
https://www.avma.org/resources-tools/reports-statistics/market-research-statistics-us-veterinarians-2018
[11]
https://www.ncba.org/beefindustrystatistics.aspx
[12]
https://www.ers.usda.gov/topics/animal-products/sheep-lamb-mutton/sector-at-a-glance/
[13]
https://www.ibisworld.com/industry-statistics/number-of-businesses/pet-stores-united-states/
[14]
https://www.statista.com/topics/1244/physicians/
[15]
https://www.aha.org/statistics/fast-facts-us-hospitals
[16]
https://www.ers.usda.gov/topics/food-markets-prices/processing-marketing/manufacturing/
[17]
https://www.cnbc.com/2016/05/19/superbugs-could-cost-100-trillion--and-millions-of-lives--by-2050-report.html
[18]
https://hbr.org/2019/05/to-improve-food-inspections-change-the-way-theyre-scheduled
[19]
https://www.nrdc.org/experts/david-wallinga-md/cdc-deaths-drug-resistant-infections-rise